Embecta (NASDAQ:EMBC) Announces Quarterly Earnings Results

Embecta (NASDAQ:EMBC) issued its quarterly earnings results on Thursday. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.20, Zacks reports. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Embecta updated its FY 2025 guidance to 2.700-2.900 EPS.

Embecta Stock Down 1.7 %

Shares of NASDAQ EMBC opened at $17.42 on Friday. The firm’s fifty day moving average is $19.65 and its 200 day moving average is $16.53. Embecta has a 52 week low of $9.93 and a 52 week high of $21.48. The company has a market cap of $1.01 billion, a price-to-earnings ratio of 17.42, a PEG ratio of 0.95 and a beta of 1.20.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 14th. Stockholders of record on Friday, February 28th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date is Friday, February 28th. Embecta’s dividend payout ratio (DPR) is presently 60.00%.

Analyst Ratings Changes

Several equities analysts recently commented on EMBC shares. Morgan Stanley raised shares of Embecta from an “underweight” rating to an “equal weight” rating and increased their target price for the company from $13.00 to $20.00 in a report on Monday, December 2nd. BTIG Research raised Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price objective on the stock in a research note on Wednesday, November 27th.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.